These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32272784)

  • 1. The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.
    Berning P; Hennemann C; Tulotta C; Schaefer C; Lechtape B; Hotfilder M; El Gourari Y; Jürgens H; Snaar-Jagalska E; Hempel G; Dirksen U; Potratz J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
    Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
    PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
    Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
    Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
    Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
    Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
    LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
    Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
    Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
    Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.
    Cazes A; Childers BG; Esparza E; Lowy AM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
    Baird AM; Easty D; Jarzabek M; Shiels L; Soltermann A; Klebe S; Raeppel S; MacDonagh L; Wu C; Griggs K; Kirschner MB; Stanfill B; Nonaka D; Goparaju CM; Murer B; Fennell DA; O'Donnell DM; Barr MP; Mutti L; Reid G; Finn S; Cuffe S; Pass HI; Opitz I; Byrne AT; O'Byrne KJ; Gray SG
    Front Endocrinol (Lausanne); 2019; 10():89. PubMed ID: 30863365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
    BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.
    Chakedis J; French R; Babicky M; Jaquish D; Mose E; Cheng P; Holman P; Howard H; Miyamoto J; Porras P; Walterscheid Z; Schultz-Fademrecht C; Esdar C; Schadt O; Eickhoff J; Lowy AM
    Oncotarget; 2016 Jul; 7(29):45959-45975. PubMed ID: 27323855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.
    Wang X; Yennawar N; Hankey PA
    Cell Commun Signal; 2014 Apr; 12():28. PubMed ID: 24739671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.
    Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Int J Clin Exp Med; 2015; 8(11):20778-86. PubMed ID: 26885001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
    Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
    Front Oncol; 2019; 9():1377. PubMed ID: 31867280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.
    Park JS; Choi HI; Kim DH; Kim CS; Bae EH; Ma SK; Kim SW
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31690042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
    Ruiz-Torres SJ; Benight NM; Karns RA; Lower EE; Guan JL; Waltz SE
    Oncotarget; 2017 Aug; 8(35):58918-58933. PubMed ID: 28938607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.